Scott L. Burrows, Chief Financial Officer at Spyre Therapeutics, Inc. (SYRE), sold 25,732 shares at $86.25 ($2.3M) on 2026-09-01, disclosed to the SEC on 2026-09-03.
Scheduled sale ($2.3M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $86.25 | 900 | $78K | 3.4% |
| 2 | $87.11 | 4,384 | $382K | 16.7% |
| 3 | $88.03 | 2,016 | $177K | 7.8% |
| 4 | $89.04 | 200 | $18K | 0.8% |
| 5 | $89.35 | 18,232 | $1.6M | 71.3% |
| Total | $88.75 avg | 25,732 |
| $2.3M |
| 100% |
| Filing → |
| SYRE | SELL | 2026-07-02 | $658K | — | Filing → |
| SYRE | SELL | 2026-06-26 | $1.3M | — | Filing → |
| SYRE | SELL | 2026-06-03 | $533K | — | Filing → |